CHChen Huo

Chen Huo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chen Huo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Jiajia Qu

    Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China

    1 shared publication
  • Jie Yao

    Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China

    1 shared publication
  • Lijun Fang

    Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China

    1 shared publication
  • Mengyu Zhang

    Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China

    1 shared publication
  • Rui Li

    Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, 250012, China

    1 shared publication
  • Yi Qu

    Department of Geriatrics, Qilu Hospital of Shandong University, Jinan 250012, China; Key Laboratory of Cardiovascular Proteomics of Shandong Province, Jinan 250012, China; Jinan Clinical Research Center for Geriatric Medicine (202132001), Jinan 250012, China

    1 shared publication

Latest Publications

  • Open Access

    PRKD1/EIF5A/β-catenin axis inhibits tumorigenesis and metastasis in non-small-cell lung cancer

    by Yu Wang, Mengyu Zhang, Lijun Fang, Jiajia Qu, Chen Huo, Rui Li, Jie Yao, Yiqing Qu

    PRKD1 is downregulated in non-small-cell lung cancer (NSCLC). Whether and how PRKD1 regulates tumorigenesis and metastasis is previously unknown. Here, we report that PRKD1 negatively regulates β-catenin protein abundance. PRKD1 promotes ubiquitination and degradation of EIF5A. EIF5A upregulates β-catenin and activates the Wnt signaling pathway. Thus, the PRKD1/EIF5A/β-catenin axis modulates the Wnt signaling pathway in NSCLC. Functionally, PRKD1 inhibits cell proliferation and metastasis both in vitro and in vivo. PRKD1 is downregulated and EIF5A is upregulated in NSCLC. Lower PRKD1 and higher EIF5A predict a worse patient survival. Our study suggests that the PRKD1/EIF5A/β-catenin axis is involved in the carcinogenesis of NSCLC and may serve as a new therapeutic target for NSCLC.